Corbus Pharmaceuticals Holdings, INC Form 4 insider transactions

Corbus Pharmaceuticals Director Winston Kung sold 2,026 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Corbus Pharmaceuticals director Anne Altmeyer sold 2,412 shares of common stock for a weighted average price of $7.9137 per share under a pre-arranged 10b5-1 trading plan.

Chief Business Officer Nishant Saxena acquired 13,500 shares of Corbus Pharmaceuticals common stock through open market purchases.

Chief Business Officer Nishant C. Saxena was granted 58,300 restricted stock units and 192,300 stock options by Corbus Pharmaceuticals.

Director Winston Kung was granted 3,800 restricted stock units and 12,300 stock options by Corbus Pharmaceuticals.

Director Rachelle Jacques received a grant of 3,800 restricted stock units and 12,300 stock options.

Director John Kenneth Jenkins was granted 3,800 restricted stock units and 12,300 stock options by Corbus Pharmaceuticals.

Corbus Pharmaceuticals director Anne Altmeyer was granted 3,800 restricted stock units and 12,300 stock options, vesting in one year.

Corbus Pharmaceuticals Holdings, Inc. director Yong Ben was granted 3,800 restricted stock units and 12,300 stock options.

Director Brent Pfeiffenberger received 7,500 restricted stock units and 24,700 stock options as part of the company's 2024 Equity Compensation Plan.

Corbus Pharmaceuticals' Chief Medical Officer, Dominic Smethurst, sold 3,285 shares of common stock to cover tax withholding obligations related to RSU vesting.

Corbus Pharmaceuticals' Chief Operating Officer, Ian Hodgson, sold 2,415 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Corbus Pharmaceuticals Holdings' Chief Medical Officer, Dominic Smethurst, received grants of restricted stock units and stock options as part of his compensation.

Corbus Pharmaceuticals' Chief Financial Officer, Sean F. Moran, was granted 28,082 restricted stock units and 84,247 stock options, aligning his incentives with the company's long-term performance.

Corbus Pharmaceuticals Holdings CEO Yuval Cohen received 50,000 restricted stock units and 150,000 stock options as part of his compensation package.

Corbus Pharmaceuticals' Chief Operating Officer, Ian Hodgson, received grants of restricted stock units and stock options, aligning his incentives with long-term company performance.

Cormorant Asset Management and related entities reported the sale of 30,029 shares of Corbus Pharmaceuticals Holdings, Inc. common stock.

Corbus Pharmaceuticals CEO Yuval Cohen exercised stock options and subsequently sold shares totaling 27,633 under a pre-arranged 10b5-1 trading plan.

Corbus Pharmaceuticals CFO Sean Moran exercised stock options and subsequently sold 12,981 shares for a significant profit, pursuant to a pre-arranged 10b5-1 trading plan.

Corbus Pharmaceuticals Director Anne Altmeyer exercised stock options and subsequently sold an equal number of common shares, as disclosed in a recent Form 4 filing.

Corbus Pharmaceuticals Director Winston Kung was granted 4,800 restricted stock units and 16,000 stock options on May 30, 2025, as part of the company's equity compensation plan.

A director at Corbus Pharmaceuticals Holdings, Inc. reported the sale of common stock under a pre-arranged trading plan, alongside the grant of restricted stock units and stock options.

Corbus Pharmaceuticals Holdings, Inc. Director Ben Yong was granted 4,800 restricted stock units and 16,000 stock options on May 30, 2025, as part of the company's equity compensation plan.

Corbus Pharmaceuticals director Anne Altmeyer sold 1,392 shares of common stock and was granted 4,800 restricted stock units and 16,000 stock options.

Corbus Pharmaceuticals Holdings, Inc. Director Alan F. Holmer was granted 4,800 restricted stock units and 16,000 stock options as part of the company's 2024 Equity Compensation Plan.

Corbus Pharmaceuticals Holdings, Inc. Director Rachelle Jacques was granted 4,800 restricted stock units and 16,000 stock options on May 30, 2025, as part of her compensation.

Dominic Smethurst, Chief Medical Officer of Corbus Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Sean F. Moran, CFO of Corbus Pharmaceuticals, sold 2,792 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Corbus Pharmaceuticals CEO Yuval Cohen sold 7,134 shares of common stock on February 14, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Dominic Smethurst, Chief Medical Officer of Corbus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.